Our industry experts anticipate that within the gastrointestinal diseases market, the GIT Anti-inflammatory drug will grow at the fastest CAGR ranging from 1% to .5%, during the forecast period. Based on the geographic regions, our experts anticipate that Europe will be the fastest-growing segment during the forecast period. The Europe region will grow at a CAGR ranging from 1% to 0.3% by 2022.
Chicago, IL -- (SBWIRE) -- 02/24/2017 -- According to the new market research report, "Gastrointestinal Diseases Market, by Drug Category (Antacid & Anti-Ulcerant, GIT Anti-inflammatory, Antiemetic, Anti-diarrhoea and Other GIT Therapeutics) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022", published by Scalar Market Research, the global gastrointestinal diseases market will grow from USD 19.79 billion in 2016 and reach USD 19.79 billion by 2022, growing at a CAGR of 2.3% during the forecast period.
The global gastrointestinal market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, key players, premium trends and forecast to 2022. It also focuses on the key drivers and opportunities in this market.
Request Sample: http://www.scalarmarketresearch.com/request-sample.php?id=12
Buyers can expect to receive 10% customization on this report.
Key findings of the report:
1. The chronic rise in the instances of gastrointestinal diseases and disorders around the world is one of the major factors creating strong demand for the products and procedures in the gastrointestinal diseases market.
2. The rapid growth in the instances of ulcerative colitis and inflammatory bowel diseases is increasing the demand in the gastrointestinal diseases market.
3. The rapid rise in the investments from the key players and the rising demand for the gastrointestinal drugs from the emerging markets will drive the growth of the gastrointestinal diseases market to some extent.
GIT Anti-inflammatory drugs: Projected to dominate the drug category segment
According to the gastrointestinal diseases market, the GIT anti-inflammatory drugs are expected to witness the fastest growth in the drug category segment of the global market. The report attributes this growth to the rising demand and the rising availability & innovations in the segment.
North America is expected to lead the global gastrointestinal diseases market
According to the report, the North America region is expected to hold the largest share in the global gastrointestinal diseases market. This dominance of North America is attributed to the rising approval of the novel drugs and the growth in the instances of various gastrointestinal diseases.
The key players highlighted in the gastrointestinal diseases market report include:
1. AstraZeneca
2. Johnson & Johnson Private Limited
3. Salix Pharmaceuticals
4. Takeda Pharmaceutical Company Limited
5. Eisai Co., Ltd.
6. Shire Plc
7. Allergan
Browse Related Reports:
Prescription Pharmaceuticals Market, by Therapeutic Segments (Cardiovascular Disorders, Inflammatory Conditions, Metabolic Disorders, Oncology, Respiratory Disorders, Others), Formulations (Capsules, Inhalants, Parenterals, Tablets, Topicals) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2020
https://www.scalarmarketresearch.com/market-reports/prescription-pharmaceuticals-market
Stem Cell Therapy Market, by Treatments (Allogeneic Stem Cell Therapy and Autologous Stem Cell Therapy), Applications (Central Nervous System Diseases, Eye Diseases, Musculoskeletal Diseases, Wound & Injuries, Metabolic Disorders, Cardiovascular Disorders, Gastrointestinal Disorders and Immune System Disorders), End-users (Hospitals and Ambulatory Surgical Centers) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022
https://www.scalarmarketresearch.com/market-reports/stem-cell-therapy-market
About Scalar Market Research
Scalar Market Research, Inc. is a Chicago, U.S.-based market research and consulting firm that serves Fortune 1000 companies, leading businesses and upcoming organizations from around the world to help them achieve their business goal of sustainable revenue growth, utilizing Scalar's premium market research reports and consulting services to make critical strategic decisions.
Our real-time industry data tracking, with the help of advanced analytics and machine learning, offers our clients highly accurate 360-degree perspective of key developments in niche markets. Our team of industry experts, with a thorough understanding of global markets and cumulative industry experience spanning 100+ years, work relentlessly to help our clients realize their most important business goals.
Find out more about our services at: www.scalarmarketresearch.com
Contact:
Mr. Moses Nakka,
8770 W Bryn Mawr Ave.,
Suite 1300
Chicago, IL 60631
Tel.: 800-213-5170 (U.S./Canada Toll-free)
Email: sales@scalarmarketresearch.com